Dr. Goetz on the MONARCH Trials for Breast Cancer

Matthew P. Goetz, MD
Published: Monday, Jan 29, 2018



Matthew P. Goetz, MD, professor of oncology and pharmacology, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the MONARCH trials for patients with breast cancer.

The secondary analysis of the MONARCH 2 and 3 clinical studies evaluated abemaciclib (Verzenio), which is an oral CDK4/6 inhibitor and hormonal therapy. The studies attempted to determine if there were any clinical or pathological factors that might be associated with the benefit of these agents.

Common variables between the 2 studies included age, race, performance status, and presence or absence of liver metastases. According to Goetz, we identified a number of factors that were prognostic including the presence or absence of liver and bone metastasis, or progesterone receptor status.

For patients who had liver metastases, the prognosis in both studies was uniformly poor but with the addition of abemaciclib, led to substantial clinically relevant increases in progression-free survival and response rates. For example, in a patient with liver metastases in the MONARCH 2 study saw an increase in response rates from 9% to 40%.



Matthew P. Goetz, MD, professor of oncology and pharmacology, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the MONARCH trials for patients with breast cancer.

The secondary analysis of the MONARCH 2 and 3 clinical studies evaluated abemaciclib (Verzenio), which is an oral CDK4/6 inhibitor and hormonal therapy. The studies attempted to determine if there were any clinical or pathological factors that might be associated with the benefit of these agents.

Common variables between the 2 studies included age, race, performance status, and presence or absence of liver metastases. According to Goetz, we identified a number of factors that were prognostic including the presence or absence of liver and bone metastasis, or progesterone receptor status.

For patients who had liver metastases, the prognosis in both studies was uniformly poor but with the addition of abemaciclib, led to substantial clinically relevant increases in progression-free survival and response rates. For example, in a patient with liver metastases in the MONARCH 2 study saw an increase in response rates from 9% to 40%.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Publication Bottom Border
Border Publication
x